Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Tb-500

Tb-500 MolecularFormula | C38H68N10O14 / MolecularWeight | 889.0 / IUPACName | (2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-4-methylpentanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]-4-carbox

By Recovery & Performance Peptides Editorial Team

Tb-500

MolecularFormulaC38H68N10O14
MolecularWeight889.0
IUPACName(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-4-methylpentanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid
  • TB500
  • 885340-08-9
  • UNII-QHK6Z47GTG
  • TB-500
  • QHK6Z47GTG
  • (2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-4-methylpentanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid
  • TB 500
  • Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH
  • L-Glutamine, N-acetyl-L-leucyl-L-lysyl-L-lysyl-L-threonyl-L-alpha-glutamyl-L-threonyl-
  • N-Acetyl-L-leucyl-L-lysyl-L-lysyl-L-threonyl-L-alpha-glutamyl-L-threonyl-L-glutamine
  • TB 500 acetate
  • (2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-4-methylpentanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid; TB 500
  • HY-P0170
  • orb1296653
  • SCHEMBL30625295
  • WZG0210
  • GLXC-23044
  • GLXC-26514
  • EX-A7411
  • MSK30023
  • C38H68N10O14
  • MFCD31692428
  • TB500?
  • TP1328
  • AKOS040763972
  • CS-6213
  • DA-58320
  • FT183581
  • MS-31657
  • G16402
  • N-Acetyl-L-leucyl-L-lysyl-L-lysyl-L-threonyl-L-|A-glutamyl-L-threonyl-L-glutamine
  • (2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-4-methyl-pentanoyl]amino]-6-amino-hexanoyl]amino]-6-amino-hexanoyl]amino]-3-hydroxy-butanoyl]amino]-4-carboxy-butanoyl]amino]-3-hydroxy-butanoyl]amino]-5-amino-5-oxo-pentanoic acid
CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosages

TB-500 dosage information primarily derives from preclinical studies and anecdotal reports, as standardized human dosing protocols remain undefined due to the absence of extensive clinical trials. In animal studies, particularly in horses, doses typically range from 500 mcg per day or 2.5 mg every 3 days, given via intramuscular injection. Regimens vary from single doses to weekly applications over several weeks, depending on the injury treated. Human use, largely based on user experiences, commonly involves subcutaneous or intramuscular injections of 2 to 5 milligrams per dose, administered one to two times per week. Treatment cycles often span four to eight weeks, followed by maintenance doses or breaks to evaluate outcomes. Due to its stability, oral administration is occasionally explored, though less common, with similar dosing ranges. The lack of regulatory approval and comprehensive human pharmacokinetic data underscores the need for caution, with users tailoring doses based on personal response. Ongoing research aims to establish evidence-based dosing guidelines for therapeutic applications.
02

Question drills

Open a question for its connected answer.

01What If TB-500 Shows No Migration Effect in Your Specific Cell Line?+

Test dose-response from 50–500 ng/mL before concluding lack of efficacy. Some cell types (particularly transformed or immortalized lines) demonstrate shifted sensitivity curves compared to primary cells. Confirm that cells express functional integrin receptors (flow cytometry for α5β1 or αvβ3) and that culture substrates support integrin engagement. TB-500's mechanism depends on coordinated integrin signaling and actin dynamics; cells grown in suspension or on non-adhesive surfaces won't respond. Consider switching to primary cells or a different model system if immortalized lines show resistance.

SOURCE / realpeptides.co ↗
02What If I Accidentally Injected Too Much Bacteriostatic Water Into the Vial?+

The peptide is still usable, but your concentration is now lower than intended. Recalculate based on the actual volume you injected. For example, if you added 3mL to a 2mg vial instead of 2mL, your final concentration is 0.67mg/mL rather than 1mg/mL. Adjust your dosing volume accordingly to deliver the correct peptide dose. Do not attempt to remove excess water from the vial or add additional powder to compensate. Both introduce contamination risk.

SOURCE / realpeptides.co ↗
03What If Your Institution Requires Additional Safety Documentation?+

Some IRBs require a full Material Safety Data Sheet (MSDS) even for research-grade peptides. Request the MSDS from your supplier. 503B facilities are required to provide it. The MSDS for TB-500 will classify it as non-hazardous under OSHA standards but will specify handling precautions (gloves, eye protection) and disposal requirements. If your institution requires biosafety committee approval in addition to IRB approval, prepare a protocol summary explaining the peptide's mechanism (actin-binding protein fragment), expected exposure routes (none for properly conducted in vitro work), and emergency procedures for accidental exposure.

SOURCE / realpeptides.co ↗
04What If the Vial Was Out for Less Than 2 Hours?+

Use it immediately or within the next 24 hours, then discard any remaining solution. A brief temperature excursion causes partial denaturation. Not total loss. But the peptide's stability window is now shortened. Do not assume the standard 28-day post-reconstitution window still applies. Partial denaturation accelerates further degradation even after returning to refrigeration.

SOURCE / realpeptides.co ↗
05What If I Start TB-500 Two Weeks After the Initial Injury?+

Administer it anyway. The remodelling phase extends 6–12 weeks post-injury, and TB-500 still influences MMP activity and collagen turnover even after initial fibroblast infiltration. Delayed dosing showed 15–20% benefit in rodent models compared to no treatment, though this was reduced from the 30–40% benefit seen with immediate administration. The practical implication: you've missed the peak migration window, but collagen quality improvement remains possible.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Research Applications:

Wound healing Inflammation Injury recovery General anti-aging research

RESEARCH

Optimizing Your Research Protocols with High-Purity Peptides

When delving into the intricate world of TB-500 corneal repair, the quality of your research materials directly impacts the validity and reproducibility of your findings. It's not just a minor detail; it's the bedrock. Inferior peptides, tainted with impurities or lacking precise amino acid sequencing, can lead to ambiguous data, wasted resources, and ultimately, stalled progress. Our clients consistently tell us that the peace of mind that comes with knowing their peptides are of the highest standard is invaluable. We take that responsibility very seriously. At Real Peptides, our commitment to small-batch synthesis means we maintain unparalleled control over the production process, ensuring every vial of TB-500 (thymosin Beta-4) meets our rigorous purity standards. This meticulous approach is designed to give you, the researcher, the best possible foundation for your studies into TB-500 corneal repair. Whether you're investigating specific cellular mechanisms or exploring broader therapeutic applications, consistent, high-purity peptides are your greatest allies. Explore High-Purity Research Peptides on our website today. The scientific journey is often a demanding one, requiring relentless dedication and an unflinching commitment to precision. We understand these challenges intimately because we're part of this community. By providing research-grade peptides that consistently meet the most exacting standards, we aim to empower you to focus on the science itself, confident in the quality of your foundational materials. It's about enabling discovery, pure and simple. The landscape of ocular medicine is undoubtedly undergoing a profound transformation. As we look at the advancements in 2026, the ongoing research into TB-500 corneal repair stands out as a beacon of hope for enhancing the body's innate ability to heal. It represents a sophisticated approach to regenerative medicine, moving beyond mere repair to aim for genuine restoration. We're incredibly optimistic about what the future holds for this remarkable peptide and its role in reshaping the outcomes for corneal health challenges.

POTENTIAL BENEFITS

What Are the Benefits of TB-500?

By supporting cellular repair and regeneration pathways, TB-500 may offer several wellness-focused benefits, including:
05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles